Taaleri reported Q2 EBIT of EUR 2.4m, coming clearly below Refinitiv consensus at EUR 5.
Biovica recently hosted a post-FDA approval commercial update for DiviTum on the 18th of August.
Redeye comments on Westpay’s Q2 results, which came in slightly better than expected in terms of mar...
Redeye returns with a more detailed take on the Q2 report and concludes that the slow sales ramp-up ...
Redeye continues to see an interesting long term investment case.
Redeye states that the Q2 report was exceptionally strong, with special emphasis on Investment Manag...
Redeye provides its comments on SenzaGen’s 2022 half-year report.
Redeye comments on Dignitana’s Q2 report. Sales continue to develop well, even if we had hoped for e...
Redeye retains its optimistic view on CombinedX despite lowering its Base Case and forecasts slightl...
Redeye states that the Q2 report was strong on all fronts.
Estimate changes driven mainly by accounting changes.
Organic sales growth of 10.5% vs. ABGSCe of 5.7% Temporary gross margin pressure in H2’22e… …but opt...
Lower margins on installations, product margins stable Near-term cost base re-assessed Fair value SE...
Finepart publicerade idag den 18 augusti 2022 bolagets delårsrapport för andra kvartalet 2022.
Redeye states that the Q2 report was strong, with solid density improvements resulting in a signific...
Guidance upgrade, but slightly softer comments into H2e EBITA +9% (2% org, 7% FX), expect lower grow...
AcuCorts användarvänliga kortisonfilm ISICORT® har erhållit godkännande från Läkemedelsverket i Sver...
Sales 7% above our expectations… …but adj. EBITA 23% below Management intends to ramp up M&A pace Q...
TCECUR avslutar H1-22 med flaggan i topp där den nyligen presenterade Q2-rapporten visade stark till...
Prostatype Genomics has secured a SEK 22.5m rights issue (pre-cost of some SEK 3.
